Equities

Indaptus Therapeutics Inc

INDP:NAQ

Indaptus Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.29
  • Today's Change-0.20 / -8.03%
  • Shares traded32.22k
  • 1 Year change+30.11%
  • Beta1.4724
Data delayed at least 15 minutes, as of Mar 28 2024 14:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

  • Revenue in USD (TTM)0.00
  • Net income in USD-15.42m
  • Incorporated2021
  • Employees7.00
  • Location
    Indaptus Therapeutics Inc3 Columbus Circle, 15Th FloorNEW YORK 10019United StatesUSA
  • Phone+1 (646) 427-2727
  • Websitehttps://indaptusrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Calidi Biotherapeutics Inc0.00-28.74m20.17m38.00---------0.6324-0.63240.00-0.02410.00----0.00-284.51-----------------25.251.25---89.98---132.57------
Onconova Therapeutics Inc226.00k-20.18m20.37m16.00--1.40--90.15-0.9628-0.96280.01080.69120.0064--9.8314,125.00-57.00-73.40-75.02-105.42-----8,930.97-2,496.26----0.00--0.00-22.08-17.33------
Pharmacyte Biotech Inc0.00-14.82m20.65m2.00--0.6627-----1.64-1.640.005.740.00----0.00-1.53-13.35-1.62-13.70------------0.00-------1.81------
Eom Pharmaceutical Holdings Inc0.00-4.93m20.73m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
Synlogic Inc3.37m-57.28m20.73m6.00--0.3833--6.15-11.41-11.410.65814.640.0362----561,833.30-61.46-40.57-74.45-43.82-----1,699.26-3,245.93----0.00009--185.685.9913.40---48.05--
Neurobo Pharmaceuticals Inc0.00-11.83m21.06m4.00--0.9674-----6.57-6.570.004.490.00----0.00-69.64-117.77-85.61-175.28-----------6.130.00------8.62------
KALA BIO Inc0.00-46.42m21.14m34.00--1.88-----22.73-22.730.004.170.00----0.00-63.23-54.04-96.42-63.22-------1,642.63---11.620.7512---65.37--68.57---8.20--
Galecto Inc0.00-38.35m21.15m13.00--0.6541-----1.45-1.450.001.190.00----0.00-68.84-48.46-81.18-52.36------------0.00------37.77------
Indaptus Therapeutics Inc0.00-15.42m21.26m7.00--1.73-----1.84-1.840.001.440.00----0.00-71.76-66.55-83.87-81.23------------0.00-------7.68------
Iterum Therapeutics PLC0.00-31.10m21.36m14.00--6.04-----2.44-2.440.000.26320.00----0.00-55.89-120.83-71.18-190.99-------40,639.07----0.8509------51.47---40.22--
AIM ImmunoTech Inc193.00k-20.78m21.64m22.00--0.9866--112.11-0.429-0.4290.0040.46320.0052--8.048,772.73-56.04-39.18-62.45-41.4984.46-262.90-10,764.25-7,630.97----0.00--4.44-20.25-1.66--31.47--
Zivo Bioscience Inc27.65k-7.78m21.75m8.00------786.58-4.62-4.620.0163-0.92590.0206----3,456.25-580.66-376.60----41.99---28,127.23-96,315.32---97.39--------11.07------
Movano Inc0.00-31.25m21.79m34.00--4.07-----0.7704-0.77040.000.09730.00----0.00-208.03---310.26--------------0.00-------25.01------
Qilian International Holding Group Ltd46.47m-7.78m21.81m298.00--0.5097--0.4693-0.2176-0.21761.301.200.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
Earth Science Tech Inc5.98m330.94k22.04m8.0072.9210.2141.643.680.0010.0010.01950.00693.1611.41106.07747,970.0017.50-224.8442.70--62.2937.795.53-333.580.386-0.38990.1023--243.77-36.31-111.95------
Context Therapeutics Inc0.00-23.96m22.07m5.00--1.86-----1.50-1.500.000.74350.00----0.00-88.71---102.79--------------0.00-------61.53------
Data as of Mar 28 2024. Currency figures normalised to Indaptus Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

7.11%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2023256.27k3.05%
The Investment House LLCas of 31 Dec 2023102.44k1.22%
Geode Capital Management LLCas of 31 Dec 202354.77k0.65%
Strategy Asset Managers LLCas of 31 Dec 202345.34k0.54%
Pine Valley Investments LLCas of 31 Dec 202344.24k0.53%
Renaissance Technologies LLCas of 31 Dec 202329.40k0.35%
Vivaldi Capital Management LPas of 31 Dec 202324.00k0.29%
SSgA Funds Management, Inc.as of 31 Dec 202319.47k0.23%
Citadel Securities LLCas of 31 Dec 202316.52k0.20%
Tower Research Capital LLCas of 31 Dec 20234.70k0.06%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.